Fast Company · Mar 2026
Fast Company named Vivodyne one of the most innovative biotech companies of 2026, citing its automated biological data centers that test 10,000 human tissues at once and its use by top pharmas such as GSK.
Human organ-on-chip platform for drug discovery.
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Vivodyne is a biotechnology research company that builds predictive human-data platforms for drug discovery and development using lab-grown 3D human tissues, robotics, and AI to generate preclinical human data before clinical trials.
Primary product
A robotics + AI platform for scalable testing on lab-grown human tissues / human organ models for preclinical drug discovery and development.
Founded
2020
Headquarters
San Francisco, California, United States
Team size
30-40
Industry
Biotechnology Research
Sub-industry
Preclinical drug discovery / human tissue engineering / organ-on-chip / bio-AI
Offices
Business model
Leadership
CEO / Co-Founder
CSO / Co-Founder
Julie O’Shaughnessy
Chief Operating Officer
Chief Biotechnology Officer
Sanja Menicanin
VP of Product
VP of Hardware and Automation
Senior Manager Business Operations
Scientific Strategy & Business Development
Senior Director, Business Development
Senior Director, Tissue Development
Public materials emphasize ambitious, mission-driven work at the intersection of biology, robotics, and AI, with a focus on building a high-performance team. No detailed public benefits package was found.
Compensation
No public compensation bands were found in the searched primary sources and company pages.
Pricing
Not publicly disclosed; likely enterprise platform/service contracts for pharma and biotech customers.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
2.7K
Traffic estimate as of Jun 2026
Fast Company · Mar 2026
Fast Company named Vivodyne one of the most innovative biotech companies of 2026, citing its automated biological data centers that test 10,000 human tissues at once and its use by top pharmas such as GSK.
Penn Center for Innovation · Jul 2025
University-affiliated source confirming Vivodyne’s Penn roots and the financing to scale its platform.
The Philadelphia Inquirer · Jun 2025
Confirms the new round, prior $38M raise, headcount around 40, and expansion plans in South San Francisco.
Hit Consultant · May 2025
Summarizes the funding and expansion into a new robotic lab facility.
Axios · May 2025
Axios reported the round and highlighted Vivodyne’s San Francisco base and its use of lab-grown human tissues for drug discovery and development.
6 jobs at Vivodyne